PUBLIC COMPANY
saveLife Biosciences Inc.
updated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
🐶 Hiring Signal
News
- STAT+: How the No Surprises Act’s nonprofit arbitrators are operating like ‘mini gods’ and getting rich doing itA STAT investigation found that several nonprofits are raking in massive sums by acting as arbitrators in a program that helps protect patients from surprise medical bills.stat · 26d ago
- After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forwardA schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna.stat · 1mo ago
- Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared to “go slow before we go fast.”stat · 1mo ago
- STAT+: FDA adcomm members’ ties to industry under scrutinyNew research found that nearly 40% of FDA advisory meetings held over a recent 20-year period included either a patient or consumer rep with active ties to an advocacy group…stat · 1mo ago
- STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drugPatient advocates and some experts are expressing growing alarm over the perceived risks of a rare disease drug sold by Neurocrine Biosciences.stat · 1mo ago
- STAT+: Hospitals sue – again – to halt Trump administration’s 340B rebate pilotThe AHA is once again suing the Trump administration over its plan to revamp a federal drug discount program into one that provides after-the-fact rebates instead of upfront discounts.stat · 1mo ago
- STAT+: Medicare Advantage star ratings trigger new bonuses, and uncertaintyThe federal government has released new quality ratings for Medicare Advantage insurers for 2027, with Humana emerging as the biggest winner.stat · 1mo ago
- STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drugLife Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.stat · 1mo ago
- City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debutPlus news about Alchemist Capital, Newron Pharmaceuticals, Life Biosciences, Onyx Bio and Tecentriq. City Therapeutics charts $158M IPO: The RNAi startup from former Alnylam executives is looking t…endpoints · 1mo ago
comments(0)
5-min edit window · permanent after that